Clinical Trial Update: Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with standard chemotherapy, tumor-infiltrating lymphocytes, and high- or low-dose aldesleukin in patients with metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Proleukin (aldesleukin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2025-01-15